Prognostic markers in gliomas

Future Oncology

Volumn 6, Issue 5, 2010, Pages 733-739

  Labussiere, Marianne ^a,b,c   Wang, Xiao Wei ^a,b,c   Idbaih, Ahmed ^a,b,c,d   Ducray, Franois ^e   Sanson, Marc ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔPITAL NEUROLOGIQUE   (France)

Author keywords

1p19q codeletion; Diffuse gliomas; Isocitrate dehydrogenase 1; Isocitrate dehydrogenase 2; O6 methylguanine DNA methyltransferase; Predictive and prognostic marker

Indexed keywords

ALPHA INTERNEXIN; ARGININE; BIOCHEMICAL MARKER; CARMUSTINE; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCINE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; LEUCINE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; PROTEIN P53; SERINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VALINE; VINCRISTINE;

ADJUVANT THERAPY; AMINO ACID SUBSTITUTION; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CARCINOGENESIS; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL (TOPIC); GENE MUTATION; GENETIC ANALYSIS; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

BRAIN NEOPLASMS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77952471455     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.25     Document Type: Review

References (57)

1. Stupp R, Mason WP, van den Bent MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352 (10), 987-996 (2005).
2. Louis DN, Ohgaki H, Wiestler OD et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114 (2), 97-109 (2007).
3. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY: Primary brain tumours in adults. Lancet 361 (9354), 323-331 (2003).
4. Purow B, Schiff D: Advances in the genetics of glioblastoma: are we reaching critical mass? Nat. Rev. Neurol. 5 (8), 419-426 (2009).
5. Bromberg JE, van den Bent MJ: Oligodendrogliomas: molecular biology and treatment. Oncologist 14 (2), 155-163 (2009).
6. Jenkins RB, Blair H, Ballman KV al et.: A t (1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66 (20), 9852-9861 (2006). • Demonstrates that the 1p19q codeletion is owing to a reciprocal translocation between chromosomes 1 and 19.
7. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol. 145 (5), 1175-1190 (1994).
8. Cairncross JG, Ueki K, Zlatescu MC et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 90 (19), 1473-1479 (1998).
9. Bauman GS, Ino Y, Ueki K et al.: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int. J. Radiat. Oncol Biol. Phys. 48 (3), 825-830 (2000).
10. Cairncross G, Berkey B, Shaw E et al.: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 24 (18), 2707-2714 (2006).
11. Fallon KB, Palmer CA, Roth KA et al.: Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J. Neuropathol. Exp. Neurol. 63 (4), 314-322 (2004).
12. Kaloshi G, Everhard S, Laigle-Donadey F et al.: Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology 70 (8), 590-595 (2008).
13. van den Bent MJ, Carpentier AF, Brandes AA et al.: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol. 24 (18), 2715-2722 (2006).
14. Weller M, Berger H, Hartmann C et al.: Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin. Cancer Res. 13 (23), 6933-6937 (2007).
15. Ricard D, Kaloshi G, Amiel-Benouaich A et al.: Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann. Neurol. 61 (5), 484-490 (2007).
16. Ducray F, El Hallani S, Idbaih A: Diagnostic and prognostic markers in gliomas. Curr. Opin. Oncol. 21 (6), 537-542 (2009).
17. Ichimura K, Vogazianou AP, Liu L et al.: 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 27 (14), 2097-2108 (2008).
18. Idbaih A, Marie Y, Pierron G et al.: Two types of chromosome 1p losses with opposite signifcance in gliomas. Ann. Neurol. 58 (3), 483-487 (2005).
19. Griffn CA, Burger P, Morsberger L et al.: Identification of der (1;19) (q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J. Neuropathol. Exp. Neurol. 65 (10), 988-994 (2006).
20. Benetkiewicz M, Idbaih A, Cousin PY et al.: NOTCH2 is neither rearranged nor mutated in t (1;19) positive oligodendrogliomas. PLoS ONE 4 (1), E4107 (2009).
21. Idbaih A, Criniere E, Marie Y et al.: Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. Neuro. Oncol. 10 (4), 540-547 (2008).
22. Idbaih A, Marie Y, Lucchesi C et al.: BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int. J. Cancer 122 (8), 1778-1786 (2008).
23. 6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J. Clin. Oncol. 24 (29), 4746-4753 (2006).
24. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer 113 (3), 379-385 (2005).
25. Ducray F, Idbaih A, de Reynies A et al.: Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol. Cancer 7, 41 (2008).
26. Phillips HS, Kharbanda S, Chen R et al.: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 (3), 157-173 (2006).
27. Ducray F, Criniere E, Idbaih A et al.: α-internexin expression identifes 1p19q codeleted gliomas. Neurology 72 (2), 156-161 (2009). • Demonstrates that INA expression appears to be a simple and reliable marker of 1p19q codeletion.
28. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K: Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res. 29 (10), 3759-3768 (2009).
29. Nagarajan RP, Costello JF: Epigenetic mechanisms in glioblastoma multiforme. Semin. Cancer Biol. 19 (3), 188-197 (2009).
30. Esteller M, Garcia-Foncillas J, Andion E et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343 (19), 1350-1354 (2000).
31. Stupp R, Hegi ME, Mason WP et al.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10 (5), 459-466 (2009). •• Demonstrates that MGMT promoter methylation is an independent factor of favorable outcome for patients included in the European Organization for Research and Treatment of Cancer/National Cancer Institute of Canada 26981/22981 trial evaluating the effect of concomitant and adjuvant temozolomide versus radiotherapy alone in glioblastoma patients.
32. Herrlinger U, Rieger J, Koch D et al.: Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J. Clin. Oncol. 24 (27), 4412-4417 (2006).
33. Weiler M, Hartmann C, Wiewrodt D et al.: Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int. J. Radiat. Oncol. Biol. Phys. (2009) (Epub ahead of print).
34. Everhard S, Kaloshi G, Criniere E et al.: MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann. Neurol. 60 (6), 740-743 (2006).
35. van den Bent MJ, Dubbink HJ, Sanson M et al.: MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group study 26951. J. Clin. Oncol. 27 (35), 5881-5886 (2009).
36. Wick W, Hartmann C, Engel C et al.: NOA-04 randomized Phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27 (35), 5874-5880 (2009).
37. 6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 18 (4), 520-532 (2008).
38. Everhard S, Tost J, El Abdalaoui H et al.: Identifcation of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro. Oncol. 11 (4), 348-356 (2009).
39. Preusser M: MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol. Histopathol. 24 (4), 511-518 (2009). • Compares different techniques to determine MGMT methylation status.
40. Parsons DW, Jones S, Zhang X et al.: An integrated genomic analysis of human glioblastoma multiforme. Science 321 (5897), 1807-1812 (2008). •• Reports the sequencing of more than 20, 000 genes in 22 glioblastomas and IDH1 mutations identified for the first time.
41. Kang MR, Kim MS, Oh JE et al.: Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer 125 (2), 353-355 (2009).
42. Yan H, Parsons DW, Jin G et al.: IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360 (8), 765-773 (2009). • Demonstrates that IDH1 mutations are specifc to diffuse gliomas and result in a reduction of IDH1 enzymatic activity.
43. Sanson M, Marie Y, Paris S et al.: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 27 (25), 4150-4154 (2009). • This study, based on 404 gliomas, demonstrated that IDH1 mutations are tightly related to genomic profile but are also strong and independent prognostic markers in grade II-IV gliomas.
44. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res. 15 (19), 6002-6007 (2009).
45. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 174 (4), 1149-1153 (2009).
46. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116 (6), 597-602 (2008).
47. 132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 30 (1), 7-11 (2009).
48. Mardis ER, Ding L, Dooling DJ et al.: Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361 (11), 1058-1066 (2009).
49. Labussiere M, Idbaih A, Wang XW et al.: All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology (2010) (In Press).
50. Ichimura K, Pearson DM, Kocialkowski S et al.: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro. Oncol. 11 (4), 341-347 (2009).
51. Zhao S, Lin Y, Xu W et al.: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 α. Science 324 (5924), 261-265 (2009). • IDH1 mutation results in the inactivation of enzymatic activity and HIF-α pathway activation, which may contribute to tumorigenesis.
52. Dang L, White DW, Gross S et al.: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462 (7274), 739-744 (2009). •• Reports that mutations in the IDH1 gene result in a gain of enzyme function leading to the production of 2-hydroxyglutarate, which may contribute to gliomagenesis.
53. Aghili M, Zahedi F, Rafiee E: Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J. Neurooncol. 91 (2), 233-236 (2009).
54. Latini A, Scussiato K, Rosa RB et al.: D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats. Eur. J. Neurosci. 17 (10), 2017-2022 (2003).
55. 132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. (2009) (Epub ahead of print).
56. 132H), the most common glioma-derived mutation. Biochem. Biophys. Res. Commun. 390 (3), 547-551 (2009).
57. Collins VP: Mechanisms of disease: genetic predictors of response to treatment in brain tumors. Nat. Clin. Pract. Oncol. 4 (6), 362-374 (2007).